AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 2.75 |
Market Cap | 4.78M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | 69.72 |
PE Ratio (ttm) | 0.04 |
Forward PE | n/a |
Analyst | Buy |
Ask | 3.09 |
Volume | 7,352 |
Avg. Volume (20D) | 72,963 |
Open | 2.94 |
Previous Close | 2.86 |
Day's Range | 2.87 - 2.98 |
52-Week Range | 2.56 - 23.80 |
Beta | undefined |
About GLMD
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinica...
Analyst Forecast
According to 1 analyst ratings, the average rating for GLMD stock is "Buy." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.